Less Ads, More Data, More Tools Register for FREE

Pin to quick picksScancell Holdings Regulatory News (SCLP)

Share Price Information for Scancell Holdings (SCLP)

Share Price is delayed by 15 minutes
Get Live Data
22.25    -0.25 (-1.11%)
Bid:
22.00
Ask:
22.50
Spread: 0.50 (2.273%)
Market Cap: £230.91m
SCLP Live PriceLast checked at - London Stock Exchange

Intraday Scancell Holdings Share Chart

Director/PDMR Shareholding

22 Oct 2013 08:00

RNS Number : 0284R
Scancell Holdings Plc
22 October 2013
 



Scancell Holdings plc

("Scancell" or the "Company")

Director Share Dealing

The Company has been notified that on 21 October 2013 Lindy Durrant and Richard Goodfellow each sold 100,000 shares in the Company from their respective holdings held jointly with Scancell Employee Benefit Trust at a price of 30 pence per share.

Following these transactions their holdings in the Company are as follows:

 

Director Name

No. of shares held in own sole name post transaction

 

No. of shares held jointly with Scancell Employee Benefit Trust post transaction

 

Lindy Durrant

1,606,960

 

8,773,960

Richard Goodfellow

200,000

 

6,343,840

 

For Further Information:

 

Scancell Holdings Plc 

+ 44 (0) 20 7831 3113 

Dr Richard Goodfellow, Joint CEO 

Professor Lindy Durrant, Joint CEO 

Cenkos Securities plc:

+44 (0) 20 7397 8900

Camilla Hume

Stephen Keys

FTI Consulting

+44 (0) 20 7831 3113

Simon Conway

Mo Noonan

Dr. Reuter Investor Relations

+(0) 49 251 980 1561

Kim von Ahn

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSEAKEFAAADFFF
Date   Source Headline
28th Apr 20267:00 amRNSFDA Fast Track Designation for iSCIB1+
2nd Apr 20267:00 amRNSScancell announces CFO transition
29th Jan 20267:00 amRNSHalf-year Financial Report
26th Jan 20267:00 amRNSFDA clearance of IND application for iSCIB1+
22nd Jan 20267:00 amRNSNotice of Results
9th Dec 20257:00 amRNSContinued improvement in PFS with iSCIB1+
7th Nov 20257:00 amRNSResearch Update
30th Oct 20253:30 pmRNSResult of AGM
3rd Oct 20257:00 amRNSNotice of AGM
16th Sep 20257:00 amRNSDirector Dealing
11th Sep 20257:00 amRNSFinal Results
4th Sep 20257:00 amRNSNotice of Results
8th Aug 202512:31 pmRNSDirector Dealing
4th Aug 202510:23 amRNSDirector/PDMR Shareholding
22nd Jul 20257:00 amRNSStrong Phase 2 data on iSCIB1+ in Melanoma
16th Jul 20257:00 amRNSShare Option Exercise
25th Jun 20257:00 amRNSScancell initiates new arm in SCOPE Phase 2 study
21st May 20257:00 amRNSDirector Dealing
14th Apr 20257:00 amRNSPartnership with NHS Cancer Vaccine Launch Pad
1st Apr 20257:00 amRNSScancell to present at 2025 AACR Annual Meeting
20th Feb 20257:00 amRNSIssue of share options
17th Feb 20257:00 amRNSScancell presenting at AACR IO conference
30th Jan 20257:00 amRNSInterim Results
23rd Jan 20257:00 amRNSNotice of Interim Results
9th Jan 20257:00 amRNSModi-1 Vaccine Achieves Early Clinical Validation
9th Dec 202411:41 amRNSResult of Retail Offer and Total Voting Rights
5th Dec 202412:39 pmRNSResult of Placing and Subscription
4th Dec 20246:03 pmRNSRetail Offer for up to £1 million
4th Dec 20245:59 pmRNSProposed fundraise in excess of £8.5 million
4th Dec 20247:00 amRNSSecond Commercial License Agreement with Genmab
18th Nov 20247:00 amRNSPositive data from Phase 2 SCOPE trial with SCIB1
25th Oct 20243:26 pmRNSResult of Annual General Meeting
24th Oct 20247:00 amRNSHolding(s) in Company
22nd Oct 20247:00 amRNSScancell Appoints Dr Phil L’Huillier as CEO
1st Oct 20247:00 amRNSNotice of AGM
24th Sep 20247:00 amRNSResults Year Ended 30 April 2024
18th Sep 20247:00 amRNSNotice of Final Results
17th Sep 20247:00 amRNSStrategic Partnership with PharmaJet
2nd Sep 20247:00 amRNSScancell to attend upcoming conferences
30th Jul 20247:17 amRNSScancell Appoints Dr Nermeen Varawalla as CMO
30th Jul 20247:00 amRNSScancell Appoints Dr Nermeen Varawalla as CMO
24th Jul 20247:00 amRNSUpdate from iSCIB1+ Clinical Advisory Meeting
10th Jul 20247:00 amRNSAppointment of Dr Florian Reinaud to the Board
2nd Jul 20247:00 amRNSExtension of Convertible Loan Notes
1st Jul 20247:00 amRNSBlock Listing Return and Total Voting Rights
21st Jun 20247:00 amRNSChange of Nominated Advisor
12th Jun 20247:32 amRNSAgreement with major biotech
31st May 20247:00 amRNSScancell to attend upcoming conferences
30th May 20247:00 amRNSUpdate on ModiFY trial
24th May 20247:00 amRNSScancell to present at ASCO Annual Meeting

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.